Investment
Features
FeesSafety
Academy
More
Pluang+

Pfizer shares rise on strong 2026 start, boosted by promising cancer drug trial and solid revenue growth.

Analyst Insights
24 Mar 2026
24/7 Wall Street
View Source
Bullish
pluang ai news

Pfizer's stock has gained 6.61% in 2026, driven by strong oncology sales and a promising Phase 3 trial for a prostate cancer drug, mevrometostat. Guggenheim raised its price target to $36, citing potential upside from trial results expected in the second half of 2026 and steady non-COVID revenue growth. Key risks include drug pricing pressures, but Pfizer's diverse pipeline and consistent earnings beats support a bullish outlook. Investors will watch closely for the MEVPRO-1 trial data and continued revenue performance to gauge if Pfizer can reach this higher valuation.

More News (PFE)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App